X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (16) 16
prostate cancer (16) 16
humans (15) 15
index medicus (15) 15
oncology (10) 10
cancer (9) 9
aged (8) 8
care and treatment (8) 8
middle aged (8) 8
aged, 80 and over (7) 7
article (7) 7
cell biology (7) 7
expression (6) 6
research (6) 6
abiraterone (5) 5
analysis (5) 5
biochemistry & molecular biology (5) 5
genetic aspects (5) 5
health aspects (5) 5
prostatic neoplasms - drug therapy (5) 5
antiandrogen (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cancer therapies (4) 4
development and progression (4) 4
enzalutamide (4) 4
gene (4) 4
gene expression (4) 4
medical research (4) 4
phenylthiohydantoin - analogs & derivatives (4) 4
progression (4) 4
prostatic neoplasms, castration-resistant - drug therapy (4) 4
research paper (4) 4
survival (4) 4
tumors (4) 4
androgen receptor (3) 3
androgens (3) 3
apoptosis (3) 3
biology (3) 3
castration-resistant (3) 3
cell survival (3) 3
cells (3) 3
chemotherapy (3) 3
clinical trials (3) 3
disease progression (3) 3
dna methylation (3) 3
docetaxel (3) 3
erg (3) 3
genes (3) 3
genetics & heredity (3) 3
men (3) 3
metastasis (3) 3
multidisciplinary sciences (3) 3
prostate-specific antigen - blood (3) 3
prostatic neoplasms - genetics (3) 3
proteins (3) 3
treatment outcome (3) 3
activation (2) 2
androgen antagonists - therapeutic use (2) 2
animals (2) 2
antiandrogens (2) 2
antigen (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic agents, hormonal - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
association (2) 2
c-myc protein (2) 2
cancers and neoplasms (2) 2
castration (2) 2
cell line, tumor (2) 2
circulating tumor-cells (2) 2
clinical trials as topic (2) 2
computational biology (2) 2
cruciferous vegetables (2) 2
denosumab (2) 2
disease-free survival (2) 2
dna microarrays (2) 2
dose-response relationship, drug (2) 2
drug resistance, neoplasm - drug effects (2) 2
drug therapy (2) 2
epidemiology (2) 2
epigenesis, genetic (2) 2
epigenetics (2) 2
gene fusion (2) 2
genitourinary tract tumors (2) 2
genomics (2) 2
growth (2) 2
hypermethylation (2) 2
imidazoles - therapeutic use (2) 2
in-vivo (2) 2
increased survival (2) 2
isothiocyanates (2) 2
kallikreins - blood (2) 2
ligands (2) 2
management (2) 2
medicine (2) 2
medicine & public health (2) 2
medicine, general & internal (2) 2
metastasis-free survival (2) 2
methylation (2) 2
microarrays (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9724, pp. 1437 - 1446
Journal Article
Cell, ISSN 0092-8674, 07/2018, Volume 174, Issue 3, pp. 758 - 769.e9
Journal Article
Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2013, Volume 8, Issue 5, p. e63563
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2015, Volume 33, Issue 2, pp. 480 - 489
Journal Article
Oncotarget, ISSN 1949-2553, 08/2016, Volume 7, Issue 33, pp. 52810 - 52817
While programmed cell death 1 (PD-1) inhibitors have shown clear anti-tumor efficacy in several solid tumors, prior results in men with metastatic castration... 
Immune response | Immunotherapy | Immunology and Microbiology Section | Enzalutamide | Immunity | PD-1 | Prostate cancer | DOCETAXEL | INFILTRATION | CELL BIOLOGY | CELL LUNG-CANCER | prostate cancer | PEMBROLIZUMAB | MELANOMA | immunotherapy | PD-L1 | NIVOLUMAB | enzalutamide | IPILIMUMAB | ANTIGEN | Phenylthiohydantoin - adverse effects | Hypothyroidism - chemically induced | Humans | Middle Aged | Prostatic Neoplasms, Castration-Resistant - immunology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Myositis - chemically induced | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Hypothyroidism - immunology | Myositis - immunology | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Aged, 80 and over | Prostatic Neoplasms, Castration-Resistant - prevention & control | Prostate-Specific Antigen - metabolism | Antibodies, Monoclonal, Humanized - adverse effects | Phenylthiohydantoin - immunology | Drug Administration Schedule | Programmed Cell Death 1 Receptor - metabolism | Antineoplastic Combined Chemotherapy Protocols - immunology | Prostatic Neoplasms, Castration-Resistant - metabolism | Remission Induction | Phenylthiohydantoin - analogs & derivatives | Phenylthiohydantoin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Prostate-Specific Antigen - immunology | Antibodies, Monoclonal, Humanized - immunology | Drug Resistance, Neoplasm - drug effects
Journal Article
ONCOGENE, ISSN 0950-9232, 07/2019, Volume 38, Issue 28, pp. 5658 - 5669
BET bromodomain inhibitors block prostate cancer cell growth at least in part through c-Myc and androgen receptor (AR) suppression. However, little is known... 
ANDROGEN RECEPTOR | MCM PROTEINS | VARIANTS | ONCOLOGY | BIOCHEMISTRY & MOLECULAR BIOLOGY | GENETICS & HEREDITY | CASTRATION-RESISTANT | EXPRESSION | CELL BIOLOGY | Care and treatment | RNA | Prostate cancer | Analysis | Cancer | Cell culture | Antitumor agents | Castration | Transcription | Computer applications | Cell lines | c-Myc protein | Post-translation | Myc protein | Ribonucleic acid--RNA
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2014, Volume 32, Issue 5, pp. 904 - 912
Journal Article